Xcelience to Expand Headquarter Operations in Tampa
News Mar 20, 2015
Governor Rick Scott has announced the expansion of Xcelience, an international contract development and manufacturing organization (CDMO) servicing the pharmaceutical and biotechnology industries. Xcelience will expand product development services and manufacturing operations in Tampa, creating 100 new jobs and retaining another 100 jobs. Xcelience will also invest $9 million in the region as part of the expansion.
Governor Scott said, “We are proud to announce that Xcelience is adding 100 new jobs in Florida because we know that every new job helps a family in our state. We are glad that Xcelience has continued to invest and expand in Florida, and it is announcements like this that are helping our state become the global destination for jobs.”
Xcelience will increase capacity in their manufacturing facilities with a 6,000 square foot expansion at their 5415 W. Laurel Street location. In addition, Xcelience will expand its pharmaceutical development labs in a new 71,000 square foot headquarters at 4910 Savarese Circle in Tampa to support future company growth. The positions will include staff for pharmaceutical development, manufacturing, quality assurance and packaging.
“Tampa is a great place to build a base of scientific capabilities,” said Derek Hennecke, President & CEO of Xcelience. “The warm climate attracts a stable workforce, and the government at all levels is eager to help us grow and prosper. Our location puts us just a mile from the airport, making it easy for out of state clients to find us. Exciting things are coming down the pipeline for Tampa, for Xcelience, and the exciting new medical treatments we are developing with our clients.”
Xcelience provides preformulation, formulation development, analytical services, GMP manufacturing, small-scale commercial manufacturing, and global clinical supplies packaging and logistics to help companies move a drug into clinical trials. The company continues to be recognized as a leader in the industry and will be receiving six Leadership Awards at next week’s Life Science Leader CMO Award Reception in New York.
“Hillsborough County offers the workforce talent, lifestyle, and culture of innovation that global companies like Xcelience need to thrive,” said the Hon. Sandy Murman, Chair of the Hillsborough County Board of County Commissioners. “We are committed to supporting their growth and appreciate their investment in our community.”
“Xcelience’s expansion of their global headquarters here is a testament to Tampa as a top life sciences and manufacturing destination,” said City of Tampa Mayor Bob Buckhorn. “The word is out about our city as a great place for science and technology professionals to live, work and play - and that excitement is driving the growth of key innovation sectors.”
Florida’s manufacturing sector ranks among the top 10 nationally with more than 18,200 companies employing some 317,000 people statewide. In 2014 the sales tax on manufacturing equipment was temporarily eliminated, and this year Governor Scott is working with the Florida Legislature to permanently eliminate it. Also, Florida has established itself as a premier location for life science clusters, and is home to world-renowned biomedical research institutes and nearly 1,000 biotech, pharmaceutical and medical device companies.
Secretary of Commerce and Enterprise Florida President & CEO Bill Johnson said, “Today we celebrate Xcelience’s expansion in the state of Florida, and applaud their creation of 100 new jobs. Florida has become a well-known destination for both manufacturing and life sciences companies, and Florida’s pro-business climate will allow the state to become even more competitive.”
This project was made possible by the close partnerships between Enterprise Florida, the Florida Department of Economic Opportunity, CareerSource Florida and the Tampa Hillsborough Economic Development Corporation.
Florida Department of Economic Opportunity Executive Director Jesse Panuccio said, “Xcelience’s expansion is another positive chapter in Tampa’s economic turnaround the last few years. The Scott administration will continue to support pro-growth policies that help the manufacturing and biotech sectors thrive in Florida. Successes such as these move us closer to our goal of making Florida the best state in which to live, learn, pursue a career, and start or grow a business.”
“Successful companies such as Xcelience know their current and future competitiveness in the global marketplace is linked to their ability to maintain a highly skilled workforce,” said CareerSource Florida President & CEO Chris Hart IV. “The training funds we are providing from CareerSource will help ensure employees at this expanding biotech business have the right skills at the right time to prosper.”
Xcelience joins an increasing number of life sciences and manufacturing industry companies that have decided to expand in Tampa and Hillsborough County, including Bristol-Myers Squibb, Covidien, HealthPlan Services, Synergy Health, Smart Science Labs, and LifeLink.
Rick Homans, President & CEO of the Tampa Hillsborough Economic Development Corporation, said, "Xcelience is another prime example of a locally headquartered company with a global reputation whose growth is helping to shape Hillsborough County’s economic future. The strength and diversity of our manufacturing, life sciences, and technology sectors are attracting more world class companies and talent to Tampa each year.”
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE
Cocaine Use Alters Gene Expression in Brain Reward CircuitsNews
A study in Biological Psychiatry investigates transcriptome-wide alterations in response to cocaine self-administration in mice.
Ipsen and MD Anderson Announce Bench-to-Bedside Cancer Drug Development PartnershipNews
MD Anderson will progress the drug candidate through Phase I clinical development with Ipsen being responsible for further global development and commercialization.READ MORE
Comments | 0 ADD COMMENT
10th Annual Congress on Drug Formulation & Analytical Techniques
Sep 03 - Sep 04, 2018